Efforts to eliminate hepatitis gain momentum

Efforts to eliminate hepatitis gain momentum PharmacoEconomics & Outcomes News 784, p2 - 12 Aug 2017 Efforts to eliminate hepatitis gain momentum New WHO data reveal that efforts to eliminate hepatitis are gaining momentum in 28 countries which account for 70% of the global hepatitis burden. The data were published on World Hepatitis Day and shows that nearly all of the 28 countries have set up high-level national hepatitis elimination committees, with over half having dedicated funding allocated for hepatitis response. Over 86% of countries reviewed have established national hepatitis elimination targets, whilst over 70% have started the development of national plans to allow access to effective services for the prevention, diagnosis, treatment and care of hepatitis. WHO Director-General, Dr Tedros Adhanom Ghebreyesus, commented that "it is encouraging to see countries turning commitment into action to tackle hepatitis". However, WHO believes that countries need to accelerate their efforts and provide further investment in order for hepatitis elimination to become a reality. With the aim of increasing access to therapy, WHO has added the first generic version of a direct acting antiviral, sofosbuvir, to its list of pre-qualified hepatitis C medicines. A 3-month treatment course of this generic will cost $US260–$280 and can now be procured by the United Nations and financing agencies such as UNITAID. Additionally, WHO is promoting the prevention of hepatitis through injection safety via a new campaign titled "Get the Point – Make smart injection choices". The global hepatitis agenda will be further advanced during the World Hepatitis Summit to be held in Sao Paulo, Brazil, from 1–3 November 2017, which is themed "Implementing the Global health sector strategy on viral hepatitis: towards the elimination of hepatitis as a public health threat". WHO. Eliminate hepatitis: WHO. Internet Document : 27 Jul 2017. Available from: URL: http://www.who.int/mediacentre/news/releases/2017/eliminate- hepatitis/en/ 803262347 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Efforts to eliminate hepatitis gain momentum

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial